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Background
Most countries from around the world will be facing significant demographic changes over the next two decades. These changes will result in a dramatic increase in the older population and a decrease of the young. 1 The demographic changes will result in more complex surgical procedures in the elderly and consequently lead to an increase in demand for blood products and a sharp drop in donations from a lack of young donors. This looming shortfall has to be addressed urgently.
The transfusion of red blood cells (RBC) for the correction of anemia is a widely accepted treatment modality and a common occurrence in the perioperative period. In the US, 16 million units of blood are collected each year but only 20% of all transfusions are given for hemorrhagic shock to the hemodynamically unstable patient and may therefore be potentially lifesaving. 2 Most RBCs are prescribed to stable patients according to empirical guidelines. However, guidelines appear to be frequently ignored or underutilized and many clinicians revert to transfusion practices based on individual beliefs. 3 Despite an increasing body of evidence that perioperative allogeneic transfusion contributes to negative outcomes, such as increased length of stay (LOS), increased infection rates, increased occurrence of transfusion-related lung injury (TRALI), transfusion-related circulatory overload (TACO) and the high number of deaths, this form of anemia management continues. 2 Many of these transfusion events can be avoided if more attention is spent on optimizing preoperative hemoglobin values and the patients iron status. Iron deficiency anemia (IDA) is a common condition. Age, socioeconomic circumstances, poor nutrition, and physiological processes (i.e. pregnancy) can result in anemia. 4 Many pathological states also commonly lead to severe iron depletion. These include inflammatory bowel disease, colorectal cancer and menorrhagia. In patients presenting for surgery iron deficiency, with or without anemia, is found in up to 75% of non-cardiac surgical patients. 5 This frequently results in an increased number of cardiac complications, days in hospital, allogeneic transfusion events and deaths. A more recent publication confirmed the incidence of anemia and stated that even mild forms of anemia increase 30-day mortality. 6 These findings imply that preoperative anemia screening and correction should become an integral part of the preoperative assessment and management process.
In many countries transfusion-related costs are of no consequence to the physician or the patient. In some countries like Australia, these costs are not even of any consequence for the hospital. This situation does not provide a platform for initiatives to facilitate change.
Patients from these high risk groups should be assessed, ideally at least four weeks prior to major surgery particularly. This would allow clinicians to interpret blood results with a window of opportunity to act. If the surgery is not urgent a delay should also be considered to investigate the cause of the anemia. In the common occurrence of iron deficiency anemia, there is increasing evidence that in urgent cases a more contemporary approach with intravenous iron might benefit the patient.
7
The economic benefits of preoperative anemia correction are difficult to assess. Cost of transfusion and transfusion-related morbidity has to be balanced against the cost of robust preoperative anemia management. The Canadian Ontario Transfusion Coordinators (ONTraC) program placed a network of nurse transfusion coordinators in 23 hospitals. These hospitals accounted for 65% of allogeneic red blood cell transfusions. Most hospitals reduced their red cell consumption significantly allowing for estimated potential annual cost savings of 14.6 million Canadian dollars.
8
A preliminary search of MEDLINE, The Cochrane Library, Embase, and Health Business Elite found no existing systematic reviews of effectiveness evidence and economic evidence on intravenous iron administration on the correction of iron deficiency anemia in the preoperative period.
Therefore this systematic review will aim to critically appraise, synthesize and present the best available evidence related to the effectiveness and economic cost-benefit ratio of intravenous iron administration on the correction of preoperative iron deficiency anemia.
Objectives
The quantitative objective is to identify the effectiveness of intravenous iron administration on the correction of iron deficiency anemia in the preoperative period.
More specifically, the objectives are to identify the effectiveness of iron infusion on the rate of RBC transfusion, the incidence of transfusion-related comorbidities such as postoperative infection, immunological morbidity and mortality, as well as changes in functional capacity that could impact on quality of life.
The economic objective of this review is to identify the cost aspects of anemia management. More specifically, the objectives are to identify the evidence of cost benefits on preoperative anemia correction and the potential for cost savings on blood products and indirect cost savings on transfusion related adverse effects.
Inclusion criteria

Types of participants
The quantitative component and also the economic component of the review considered studies that included adult patients older than18years presenting for major surgery, regardless of gender, ethnicity, diagnosis and co-morbidities with preoperative anemia.
Types of intervention(s)/phenomena of interest
The quantitative component of the review considered studies that evaluated the management of anemia with iron infusions compared to oral iron treatment alone, oral iron in combination with erythropoietin, erythropoietin alone, or hemoglobin correction with blood transfusion. This included the dosage of iron, the frequency of its administration and the timeframe of treatment prior to surgery. In addition, it also assessed how intervention was employed, the personnel involved and the time spent to complete management.
The economic component of this review considered studies that evaluated the costs and benefits (costeffectiveness, cost-utility, or cost-benefit) of iron infusions compared to oral iron treatment or hemoglobin correction with blood transfusion for the treatment of preoperative anemia.
Types of studies
The quantitative component of the review considered any experimental study design, including RCTs, non-RCTs, quasi-experimental, and before and after studies, for inclusion.
The economic component of the review considered cost effectiveness, cost-utility, and cost-benefit studies for inclusion.
Types of outcomes
The quantitative component of this review considered studies that included (but was not limited to) the following outcome measures:
• Effect of iron administration on hemoglobin levels
• Rate of RBC transfusion measured as proportion of patients transfused with allogeneic RBC and the average number of units transfused
• Length of stay in hospital
• Rate of readmission within 30 days of discharge
• Incidence of transfusion related co-morbidities measured as infection rates, occurrence of transfusion related lung injury (TRALI), transfusion related circulatory overload (TACO), and number of deaths.
• Impact of intravenous iron administration on functional outcomes.
The economic component of the review considered (but was not limited to) the following outcome measures:
• Reduction in costs for units of allogeneic blood avoided JBI Database of Systematic Reviews & Implementation Reports 2013;11 (10) • Reduction in costs associated with a reduction in length of stay in hospital
• Reduction in transfusion laboratory costs and nursing time
• Increase in costs for iron administered and nursing time.
Search strategy
The search strategy aimed to find both published and unpublished studies. A three-step search strategy was utilized in this review. An initial limited search of MEDLINE was undertaken followed by an analysis of the text words contained in the title and abstract, and of the index terms used to describe the articles.
A second search using all identified keywords and index terms was then undertaken across all included databases. Next, the reference list of all identified reports and articles was searched for additional studies. Studies published in English, German, Italian and Dutch were considered for inclusion in this review. Awareness of transfusion and anemia related outcomes have been addressed over the last 10
years. Therefore studies published from 2001 to December 2012 were considered for inclusion in this review.
The databases searched included:
• PubMed
• EMBASE
• The Cochrane Library
• Health Business Elite database • NHS Economic Evaluation Database (NHS EED)
• Health Economic Evaluation Database (HEED).
The search for unpublished studies included: MedNar and ProQuest Dissertation and Thesis.
Method of the review
Quantitative papers selected for retrieval was assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardized critical appraisal instruments from the Joanna Briggs Institute Meta-Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI) (Appendix V). Any disagreements that arose between the reviewers was resolved through discussion, or with a third reviewer.
Economic papers selected for retrieval were assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardized critical appraisal instruments from the Joanna Briggs Institute Analysis of Cost, Technology and Utilization Assessment and Review Instrument (JBI-ACTUARI) (Appendix V). Any disagreements that arose between the reviewers were resolved through discussion, or with a third reviewer.
Data collection
Quantitative data was extracted from papers included in the review using the standardized data extraction tool from JBI-MAStARI (Appendix VI). The data extracted included specific details about the interventions, populations, study methods and outcomes of significance to the review question and specific objectives.
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Economic data was extracted from papers included in the review using the standardized data extraction tool from JBI-ACTUARI (Appendix VI). The data extracted included specific details about the interventions, populations, study methods and outcomes of significance to the review question and specific objectives.
Data synthesis
Quantitative papers was, where possible, pooled in statistical meta-analysis using JBI-MAStARI. All results were subject to double data entry. Effect sizes expressed as odds ratio (for categorical data) and weighted mean differences (for continuous data) and their 95% confidence intervals were calculated for analysis. Heterogeneity was assessed statistically using the standard Chi-square. Where statistical pooling was not possible the findings were presented in narrative form including tables and figures to aid in data presentation where appropriate.
Quantitative papers were, where possible, pooled in statistical meta-analysis using JBI-MAStARI. All results were subject to double data entry. Effect sizes expressed as odds ratio (for categorical data) and weighted mean differences (for continuous data) and their 95% confidence intervals were calculated for analysis. Heterogeneity was assessed statistically using the standard Chi-square. Where statistical pooling was not possible the findings were presented in narrative form including tables and figures to aid in data presentation where appropriate.
Economic findings were, where possible, pooled using JBI-ACTUARI and presented in a tabular summary. Where this was not possible, findings were presented in narrative form.
Results
Description of studies
Seventy-nine potentially relevant papers were identified in database searches. Titles and abstracts were examined for 63 papers. Three full text papers were retrieved for comprehensive examination.
One paper was excluded after full text examination and two studies were selected for critical appraisal ( Figure 1 ). On final assessment, two studies were identified as fulfilling all of the criteria for inclusion. The first included study by Kim et al. was an open-label, prospective, randomized, multicenter trial conducted at three hospitals (including a tertiary referral center) in Seoul, Korea. 9 Patients enrolled were women with menorrhagia, where the condition resulted in IDA and hemoglobin levels of <9 g/dl.
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Patients were randomized to receive either intravenous iron sucrose or oral iron protein succinylate, starting three weeks prior to scheduled surgery. Based on a two-tailed α of 0.05, it was determined that 36 patients per group were required to detect a 1-g/dl Hb difference in the primary outcome variable with a power of 80%.
No severe adverse effects were observed in the study period. Seventy-six patients were randomized and 30 completed the study in the intravenous iron arm and 26 in the oral arm. Thirty (76.7%) patients reached the target Hb in the intravenous iron group compared with 20 (11.5%) in the oral iron group RR, 95% CI (p< 0.0001). Hb and ferritin were also significantly higher in the intravenous group at the end of the study. The intravenous iron group had a greater increase in the Hb level than the oral iron group (3.0 vs. 0.8 g/dl, respectively; p < 0.0001) associated with an increase in the ferritin level (170.1 vs. 4.1 µg/l; p < 0.0001). This was a well-conducted study in a patient cohort with significant iron deficiency anemia.
The other phenomena of interest for this review, the rate of RBC transfusion, the average number of units transfused, the length of stay in hospital, the rate of readmission within 30 days of discharge, the incidence of transfusion related co-morbidities, the number of deaths and the impact of intravenous iron administration on functional outcomes, were not reported in this study.
The second (partially) included study by Edwards et al. was a single-center study in patients with suspected bowel cancer scheduled to undergo a bowel resection. 10 The study was powered at 80% to detect a 0.5 g/dl hemoglobin change between recruitment and the day of admission. In addition the hemoglobin value on the day of hospital discharge was recorded. All patients of a particular period, fulfilling the inclusion criteria, were enrolled and allocated to a treatment (intravenous iron) group or a placebo group. No significant difference was found for the primary outcome parameter between the groups and mean changes in hemoglobin value between recruitment and at presentation for surgery were -019 g/dl for the intravenous iron group and -0.50 g/dl for the placebo group. IQR, 95%CI
(p=0.355).
Only 18 The other phenomena of interest for this review − the rate of RBC transfusion, the average number of units transfused, the length of stay in hospital, the rate of readmission within 30 days of discharge, the incidence of transfusion related co-morbidities, the number of deaths and the impact of intravenous iron administration on functional outcomes − were not reported in this study. 
Discussion
The burden of anemia
As the most common global nutritional deficiency, the burden on society resulting from anemia is immense. Anemia-related symptoms such as fatigue, impaired cognitive function and poor exercise tolerance lessen quality of life that leads to huge productivity losses.
11
The prevalence of IDA varies, depending on sources, definitions and patient cohorts. 12, 13 Iron deficiency, with or without anemia, is found in up to 75% of patients presenting for surgery. 14 A growing body of evidence suggests that this has serious consequences for the perioperative period. IDA frequently leads to an increased number of cardiac complications, an increased number of days in hospital and a greater number of allogeneic transfusion events. 3 Preoperative anemia was also shown to independently increase perioperative mortality. 5 A more recent publication involving 227,425 patients, of whom 69,229 (30.44%) had preoperative anemia, confirmed the high incidence and concluded that even mild forms of anemia increase 30-day mortality. 6 Anemia is commonly aggravated in the postoperative period. Intraoperative blood loss, wound drainage, hemodilution and frequent venipuncture for testing are all contributing factors. In addition, pre-existing iron depletion prevents effective perioperative erythropoiesis impairing post-operative functional recovery. 15 Impact on blood usage and utilization
When it comes to the surgical setting, which is the particular focus of this review, the presence of anemia often results in RBC transfusion. This continues to be a widely accepted treatment modality despite the clear and well described potential adverse effects and outcomes. 16 Donated blood is often claimed and perceived to be "safe", prompting many clinicians to transfuse as a default position. Old dogmas prevail and the decision to transfuse is not only taken lightly but also often triggers a minimum transfusion of two units. 17 This is especially important as there appears to be a significant dose dependent effect of transfusion related adverse effects. It needs to be emphasized that not only total avoidance but also minimization of exposure to blood would potentially prevent harm and benefit the patient.
18
By donating blood, donors place a valuable resource into the clinicians' hands with the assumption that it will be dealt with responsibly. This responsibility should be taken into account each time blood products are prescribed. It can however be noted that prescribing a blood transfusion is a process which remains too easy, is rarely discussed and often left to the inexperienced medical officer. 19 A common lack of documentation and/or consent accentuates the lack of scrutiny applied to the process of transfusion. The transfusion event is poorly monitored, is often inappropriate, unjustified and, due to various different funding models, sometimes comes at no cost for the health care provider (i.e. Australia). 20 These factors combined make it unlikely that clinical practice will change.
Risk groups and identification
This review highlights that many patients who present for surgery are at risk of iron deficiency. This subsequently exposes them to a number of potential complications and a higher transfusion risks. This risk increases with the type and extent of the surgery, but also with the underlying disease process. 21 
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Certain types of patients stand out and should make the clinician cautious. Patients with gastro-intestinal malignancies show the highest prevalence of IDA. 5 Chronic and longstanding blood loss results in iron loss and iron store depletion. Inflammatory bowel disease exposes patients to similar risks. 22 Women with menorrhagia often suffer from heavy menstrual bleeding for many years leading to gradual iron depletion. In these, generally otherwise healthy women, the condition is often well tolerated for a very long time and women frequently present with severe IDA to emergency departments when the tipping point is reached (personal observation). Patients scheduled for cardiac or orthopedic surgeries commonly combine many disadvantages. Advanced age, significant comorbidities such as congestive heart failure, ischemic heart disease, osteoarthritis and renal disease often compound the problem and ID and IDA becomes multifactorial. 23 An inflammatory state as a result of the chronic disease process leads to hepcidin increases and down regulation of iron absorption and utilization. 24 Certain medication may also further impair absorption (i.e. proton pump inhibitors, antacids) and other drugs can contribute to blood loss (aspirin, clopidogrel, warfarin, NSAIDs) threatening iron metabolism and iron balance. 25, 26 As many of the described findings are treatable and/or preventable it is obvious that preoperative anemia screening, detection and correction, particularly in patient groups at risk of IDA, should become an integral part of the preoperative assessment and management process. Iron deficiency with or without anemia is not a physiological state. It must therefore be considered a "disease process". In medical practice we are required to treat disease and as such, anemia correction deserves much more attention. This makes it all the more surprising that our study found such a limited numbers of related studies.
Approach to change
It is clear, however, that high level evidence alone will not guarantee knowledge translation. Conducting audits and providing feedback can be a powerful intervention and provide the adequate tool in achieving the desired change in clinical practice. 27, 27 This was reiterated very recently by a panel of experts at the International Consensus Conference on Transfusion and Outcomes held in April 2009 in Phoenix. 28 The panel concluded that there is little evidence to support a beneficial effect from the greatest number of transfusions currently being given to patients.
Experts and authorities from around the world, including the World Health Organization, have recognized the need for change and the importance of more appropriate treatment approaches. 29, 30 This can be facilitated through the implementation of Patient Blood Management (PBM) programs. It is crucial, however, that awareness is created and that PBM programs are driven by a local team underpinned by government support. Recognizing the importance of such change, accreditation, education and audit should consequently be linked in with PBM, and be compulsory. Even short educational sessions improved transfusion practice in the perioperative setting. 31 Physicians who understand transfusion indications and are receptive to input from colleagues apply a significantly higher quality transfusion practice. 32 Education, therefore, in addition to a willingness to accept "expert advice" is fundamental.
Models of practice
Pregnancy is one of the key areas where this has been explored. Pregnant women are a well-recognized risk group for developing ID and IDA. In the context of this review, the existing evidence from this patient cohort could not be included because the condition is not considered "preoperative" per se. However, 30% of women deliver by caesarean section, a surgical procedure with an average blood loss of 400 ml. In addition to this, even normal vaginal delivery is often associated with significant blood loss.
Several studies have shown significant benefits from the administration of intravenous iron compared to oral iron supplementation. 13, 33 Changes in Hb allowed women to be better prepared for delivery. This also enabled women to tolerate and recover better from blood loss associated with labor, which in 13% of women is moderate to severe. 12 Restoration of iron stores often alleviates ID-associated symptoms.
These benefits are also felt in the post-partum period by reducing the incidence of post-partum depression and prolonging breast feeding episodes. 13, 34 Therefore, despite the lack of evidence in the "surgical" population, some of the results from obstetric patients can offer insight and may be translated.
Interim solutions
In the absence of multiple RCTs in the literature providing guidance, one has to appreciate that prospective and retrospective cohort studies have described intravenous iron as an effective intervention. [35] [36] [37] Due to a high risk of serious adverse events associated with infusions of iron dextran, physicians have been cautious about intravenous intervention and have frequently substituted it with the transfusion of RBCs to correct any preoperative anemia. 38 In some clinical settings, however, it has been demonstrated that intravenous iron appears to be beneficial, particularly in iron deficient patients, with or without anemia. 37, 39 Newer types of low molecular weight intravenous irons offer a much improved safety profile resulting in significantly lower incidences of adverse effects. 40 In recent years, this has led to the expansion of licensed indications for iron sucrose and ferric carboxymaltose, for example. It is surprising therefore that this treatment has not been studied extensively and there is not enough data from RCTs to support this approach. Accumulating observational data appears promising but randomized trials are needed to evaluate efficacy and cost effectiveness. In addition to dose requirements, trials are needed to determine the ideal time of administration and to identify the patient groups most in need of this intervention.
The majority of surgery is undertaken in an elective setting. Clinicians should strive for optimal patient outcomes in an attempt to minimize morbidity and mortality. 4 The development of patient blood management guidelines should assist in addressing anemia in order to minimize patient exposure to allogeneic blood, to enhance patient recovery and contribute to overall cost savings within health sectors, already under enormous financial strain. 41 Divided into three pillars, reflecting the pre-, intraand post-operative phase, the preoperative period should focus on the detection and correction of anemia and iron deficiency. One could argue that no patient with anemia booked for elective surgery should enter the operating room. It is however crucial to identify patients with the appropriate test, communicate this well amongst involved specialties, and decide on the right strategy and treatment modality in order to achieve the best possible improvement in iron status and hemoglobin values. anemia correction could have resulted in a 40% overall reduction in hospital cost. 42 The rising costs and looming shortage and availability of RBCs add to the multiple disadvantages of allogeneic transfusions.
Analyzing the cost of transfusion in the surgical setting should involve all steps required at a hospital level, called activity based cost. This is crucial in order to reflect the true cost of blood but is very complex. Due to fundamental differences in health jurisdictions, these cost factors are not universally applicable, but it is possible to establish identifying principles. Irrespective of the health system examined, it is highly likely that the real cost of blood has been underestimated in the past. 43 Many jurisdictions are already employing implementation of tools that identify activity for blood usage and this will certainly assist in rigorous cost analysis.
Blood management has been on the agenda for some time. It is therefore surprising that, despite a vast amount of publications and multiple guidelines available, knowledge translation is lacking and many transfusion events remain inappropriate.
Unmanaged anemia leads to a significant increase in transfusion. A Canadian program demonstrated successfully improved clinical outcomes and cost savings by managing patients appropriately in the preoperative period. 3 A recent publication on the implementation of a local blood management algorithm in major orthopedic surgery illustrated that cost-savings can be achieved. 44 In a RCT setting oral iron supplementation has been shown to reduce transfusion incidence resulting in significant cost savings. 46, 45 Depending on the time frame prior to surgery and the severity of the anemia and/or iron depletion, intravenous iron administration appears to be an even more effective approach. 35, 37, 46 It is important to remember that the main target of patient care is patient outcome. Patient blood management should be standard care for all patients in the surgical setting. Even if total transfusion avoidance is not feasible for all patients, overall reductions are achievable. Endorsing appropriate transfusion approaches in combination with preoperative optimization should result in improved patient well-being, and cost savings are likely to be a logical flow on effect.
Conclusion
There is a significant gap in the literature. Our study found insufficient data to make firm conclusions about the efficacy of preoperative intravenous iron administration for the correction of anemia based on clinical trial settings. Neither could we establish firm conclusions on the potential cost savings due to intravenous iron supplementation
Implications for practice
There is inadequate RCT evidence at present to guide clinical practice.
Implications for research
An adequately powered RCT is needed to determine whether anemia can be adequately corrected and is cost effective when preoperative intravenous iron is administered.
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